<DOC>
	<DOCNO>NCT02350868</DOCNO>
	<brief_summary>The Dose Escalation Phase determine MTD MPT0E028 evaluate safety tolerability , PK , PD , preliminary clinical effect ; subsequent Dose Confirmation Phase cohort expansion MTD ( i.e. , RP2D ) MPT0E028 .</brief_summary>
	<brief_title>Dose-Seeking Study MPT0E028 Subjects With Advanced Solid Malignancies Without Standard Treatment</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1 . Males females ≥ 20 year age . 2 . Pathologically confirm advanced solid tumor , occur progressed disease treatment standard therapy , standard therapy proven provide clinical benefit exist . NOTE : For primary liver cancer , standard therapy , transcatheter arterial chemoembolization ( TACE ) , radiofrequency ablation ( RFA ) percutaneous ethanol intratumor injection ( PEI ) . 3 . Eastern Collaborative Oncology Group ( ECOG ) Performance Status ≤1 ( Appendix 1 ) . 4 . Evaluable disease , either measurable physical examination ( PE ) image Response Evaluation Criteria Solid Tumors ( RECIST v1.1 , Appendix 4 ) , informative tumor marker ( ) . 5 . Laboratory value screen : 1 . ANC ≥1,500/mm3 ; 2 . Platelets ≥100,000/mm3 ; 3 . Total bilirubin ≤1.5 × upper limit normal ( ULN ) ; 4 . Aspartate aminotransferase ( AST [ SGOT ] ) ≤2.5 × ULN ; 5 . Alanine aminotransferase ( ALT [ SGPT ] ) ≤2.5 × ULN ; 6 . Serum creatinine ≤1.5 mg/dL measure creatinine clearance ≥60 mL/min ; 7 . Negative serum beta hCG test woman childbearing potential ( defined woman ≤50 year age history amenorrhea ≤12 month prior study entry ) . 6 . Subjects primary liver cancer hepatic metastasis eligible enroll , provide , screen , follow criterion meet : 1 . Total bilirubin high ULN ; 2 . AST ALT ≤5 × ULN ; 3 . Severe liver dysfunction ( ChildPugh Class B C ) present ; 4 . Subjects history esophageal bleed varix sclerosed banded bleeding episode occur prior 6 month . 7 . If history brain metastasis treat radiation therapy , radiation therapy must occur least 6 week prior enrollment ( sign ICF obtain ) metastatic disease must stable since completion . 8 . Willing able provide write Informed Consent comply requirement study . 9 . In addition , subject enrol Dose Confirmation Phase must measurable disease , use RECIST v1.1 ( Appendix 4 ) . Exclusion Criteria 1 . Any chemotherapy , immunomodulatory drug therapy , antineoplastic hormonal therapy ( unless comprises androgendeprivation therapy subject prostate cancer dose stable 3 month prior Baseline remain stable trial ) , immunosuppressive therapy , corticosteroid &gt; 20 mg/day prednisone equivalent ( unless administer prevent contrast material reaction radiographic procedure ) , growth factor treatment ( e.g. , erythropoietin ) within 14 day prior initiation study drug . 2 . Presence acute chronic toxicity prior chemotherapy , exception alopecia peripheral neuropathy , resolve ≤Grade 1 , determine National Cancer Institute CTCAE v 4.0 ( http : //evs.nci.nih.gov/ftp1/CTCAE/About.html ) . 3 . Positive hepatitis B virus surface antigen ( HBsAg ) positive antihepatitis C virus ( HCV ) antibody . 4 . Radiotherapy within 4 week prior baseline . 5 . Receipt radiotherapy &gt; 25 % bone marrow ( Appendix 5 ) . 6 . Major surgery within 28 day prior initiation study drug . 7 . Life expectancy &lt; 12 week . 8 . Active bacterial , fungal , viral infection require systemic therapy . 9 . Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness . 10 . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 , Appendix 1 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug . 11 . History ongoing cardiac dysrhythmias require treatment , atrial fibrillation grade , persistent prolongation QTc ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female . 12 . With previous malignancy prior study entry , except 1. nonbasalcell carcinoma skin carcinomainsitu uterine cervix 2. tumor treat curative intent 2 year prior study entry . 13 . Treatment follow pharmaceutical herbal agent within 14 day prior study drug uptake : 1. know moderate severe inhibitor inducer CYP3A4 ( Appendix 2 ) . 2. known sensitive narrow therapeutic index substrate CYP3A4 , CYP2C8 , CYP2C9 , CYP2C19 ( Appendix 3 ) Note : 1 . For Docetaxel , Vincristine , Phenobarbital , Aripiprazole washout period perform ≥ 30 day , subject enrol . 2 . Subject receive Amiodarone enrol . 14 . Use investigational agent within 4 week baseline . 15 . Pregnant lactate female . 16 . Women childbearing potential , unless agree use dual contraceptive method , opinion principal Investigator , effective adequate subject 's circumstance study drug 3 month afterward . 17 . Men partner woman childbearing potential , unless agree use effective , dual contraceptive method ( i.e. , condom , female partner use oral , injectable , barrier method ) study drug 3 month afterward . 18 . Any severe , acute , chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , Investigator 's opinion , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>without Standard Treatment</keyword>
</DOC>